InvestorsHub Logo
Followers 14
Posts 730
Boards Moderated 0
Alias Born 03/14/2010

Re: Biobillionair post# 122362

Friday, 02/09/2018 4:38:45 PM

Friday, February 09, 2018 4:38:45 PM

Post# of 428989
The nice part about the AHA is they get the diff between the different contents of the drugs.
I truly see AHA favorably including high dose EPA such as Vascepa in the guidelines for multiple indications.
This would be absolutely blockbuster.
They are following this reduce it trial (and strength ) but they will update their guidelines after the reduce it trial.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News